# The THOR IDE Study

Study · id `cardio:ct-nct05916950` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05916950](<https://clinicaltrials.gov/study/NCT05916950>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05916950

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 155 participants.

## Technical summary

Registry record NCT05916950. Allocation not applicable; no masking; primary purpose treatment. Start 2024-10-29 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 155 participants (planned count; ClinicalTrials.gov record NCT05916950, source copy `cardio:ctgov-nct05916950-2026-11-05`, retrieved 2026-11-18)
- Started: 2024-10-29 (actual) (ClinicalTrials.gov record NCT05916950, source copy `cardio:ctgov-nct05916950-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT05916950, source copy `cardio:ctgov-nct05916950-2026-11-05`, retrieved 2026-11-18)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT05916950, source copy `cardio:ctgov-nct05916950-2026-11-05`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT05916950, source copy `cardio:ctgov-nct05916950-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05916950-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: The THOR IDE Study
- Acronym: THOR
- Condition: Peripheral Artery Disease
- Condition: Peripheral Artery Stenosis
- Condition: Peripheral Artery Calcification
- Condition: PAD
- Intervention (Device): Thor laser atherectomy
- Lead sponsor: Philips Clinical & Medical Affairs Global
- Lead sponsor class: INDUSTRY
- Collaborator: NAMSA
- Collaborator class: OTHER
- Collaborator: Syntropic
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Philips Clinical & Medical Affairs Global (`cardio:org-philips-clinical-medical-affairs-global`)

## Provenance

Content hash: 023a7f5b3d50f226724998a4767e6f1ef7d7b944f7418492f07047db11c7a29a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
